SNPX חוב כולל להון Synaptogenix

Synaptogenix, Inc. (SNPX) possesses significant authority in the field of nerve cell regeneration for the therapy of severe memory impairments. The market trend for the total debt-to-equity ratio is recorded at 0.00. The business relies on the development of agents for synapse renovation in dementia through the activation of protein kinase C. Scientific research is conducted within US jurisdiction, which guarantees independence from global trade conflicts.

This ratio measures the business's dependence on external borrowings relative to its own equity, reflecting the balance sheet structure's resilience to cash flow gaps. For Synaptogenix, Inc. (SNPX), whose revenues are expected only after the approval of briostatin-1, the total debt-to-equity ratio serves as an indicator of financial viability during costly clinical trials until payments are received from insurance funds.